Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIAlta
2024-519983-42-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of rifampicin + isoniazid + pyrazinamide + ethambutol and rifampicin in Tuberculosis (TB), sponsored by Vall d'Hebron Research Institute. Primary endpoint: Safety - proportion of participants with one or more serious adverse events. Planned start Feb 2025; status: authorised.
02
Drugs
rifampicin + isoniazid + pyrazinamide + ethambutolrifampicin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on 2024-519983-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519983-42-00.